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Recombinant uteroglobin prevents the experimental crescentic
glomerulonephritis.
Background. Although uteroglobin is known to have an
immunomodulatory property and prevents the deposition of
immune-complexes on the glomeruli of mice, the therapeu-
tic potential of uteroglobin is uncertain in glomerulonephri-
tis. To test the hypothesis that uteroglobin can prevent
glomerulonephritis, we have studied the effects of recombi-
nant uteroglobin on the development of experimental cres-
centic glomerulonephritis that is induced by anti-glomerular
basement membrane (anti-GBM) antibodies.
Methods and Results. Glomerulonephritis was induced by
the intravenous injection of rabbit anti-GBM globulin antibod-
ies into mice (C57BL/6), and renal injury was evaluated 7, 14,
and 21 days afterward. Recombinant uteroglobin or phosphate-
buffered saline (PBS) were given intravenously to mice for
3 days after anti-GBM antibody injection. Proteinuria was sig-
nificantly reduced in mice treated with recombinant uteroglobin
compared with disease-control mice at 7 and 14 days after
an anti-GBM antibody injection, although the serum creati-
nine concentration was similar in both groups. The amount
of proteinuria was similar in recombinant uteroglobin-treated
and normal control mice. By histologic analysis, mesangial ma-
trix expansion, mesangial proliferation, and cellular crescents
representing crescentic glomerulonephritis were markedly at-
tenuated by injection of recombinant uteroglobin. The in vitro
proliferative responses of mesangial cells to lipopolysaccharide
(LPS) were blunted by the addition of recombinant uteroglobin
in a dose-dependent manner. The preventive effects exerted
by recombinant uteroglobin treatment were based on the in-
hibition of antibodies and complement-3 deposition on the
glomeruli.
Conclusion. This study demonstrates the preventive effects
of recombinant uteroglobin in an experimental model of cres-
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centic glomerulonephritis, and suggests the therapeutic impli-
cations of uteroglobin for human chronic glomerulonephritis.
Glomerulonephritis is one of the major causes of end-
stage renal disease (ESRD) in Korea [1]. Although the
exact nature of the pathogenesis of glomerulonephritis
is still unknown, immune complex–mediated inflamma-
tory responses have been suggested as central patho-
genetic mechanism [2]. The accumulation of cells and
fibrin within Bowman’s space of glomeruli produces the
histologic appearance of a glomerular crescent. Glomeru-
lar crescent formation, the hallmark of severe and rapidly
progressive immune renal injury, is characterized by
the accumulation of T cells, macrophages, and fibrin
in glomeruli [3–5]. Among the various animal models
of glomerulonephritis, anti-glomerular basement mem-
brane (anti-GBM) disease (glomerulonephritis) has been
widely studied and seems to be the most similar counter-
part of the human disease [6–8].
Uteroglobin or Clara cell 10 kD protein is a steroid-
dependent, immunomodulatory, and cytokine-like pro-
tein [9, 10]. Moreover, it is known to be secreted by
the mucosal epithelial cells of all vertebrates studied
to date [11, 12]. Uteroglobin appears to function as an
anti-inflammatory agent, in both the respiratory and uro-
genital tracts [12], and micromolar concentrations of
uteroglobin may inhibit the chemotaxis of both neu-
trophils and monocytes and prevent the infiltration of
inflammatory cells [13]. Uteroglobin is also a potent in-
hibitor of phospholipase A2 activity [14], thereby lim-
its the metabolism of arachidonic acid and the synthesis
of prostaglandin and leukotriene mediators [15]. Zheng
et al [16] reported that two independent mouse mod-
els, both manifesting deficiency of uteroglobin, devel-
oped pathologic features of human IgA nephropathy, and
suggested that exogenous uteroglobin was sufficient to
prevent the glomerular accumulation of exogenous IgA
in uteroglobin-null mice [16].
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We examined whether exogenous recombinant
uteroglobin could prevent the development of ex-
perimental glomerulonephritis induced by anti-GBM
antibodies in mice, and also evaluated the effects of
recombinant uteroglobin on proliferative responses to
noxious stimuli on mouse mesangial cells. In addition, we
investigated the influence of recombinant uteroglobin
on immune complex deposition.
METHODS
Production of recombinant human uteroglobin
Human lung cancer cell line (NCI-H322) (ATCC,
CRL5806) was used for cloning the human uteroglobin.
To obtain the whole segment of mature uteroglobin,
reverse transcription-polymerase chain reaction (RT-
PCR) was conducted using CC10-1 (sense primer
5′-CCAGACTCAGAGACGGAA-3′) and CC10-2 (an-
tisense primer 5′-CATATGAAACTCGCTGTCACC-
3′). Nested PCR was performed after first round
PCR using CC10-3 (sense primer 5′-CTCGAGCTAATT
ACACAGTGAGCT-3′) and CC10-4 (antisense primer
5′-GACTCAAAGCATGGCAGC-3′). PCR product was
cloned into pET32a plasmid (Novagen, Madison, WI,
USA). Recombinant uteroglobin was produced from
transformed Escherichia coli BL21. His-tagged recom-
binant uteroglobin was purified by Ni++-affinity chro-
matography (Novagen). Centricon (Millipore, Bedford,
MA, USA) was used to concentrate the recombi-
nant protein after dialysis, and the Bradford assay was
used to quantify the protein (Bio-Rad Laboratories,
Hercules, CA, USA). Recombinant uteroglobin was
confirmed by Western blot where polyclonal rabbit an-
tihuman uteroglobin antibody (urine protein 1) (Dako-
Cytomation, Glostrup, Denmark) was used as primary
antibody (data not shown).
Induction of anti GBM disease
Anti-GBM antibody was prepared from the serum of
a rabbit immunized against homogenized murine renal
cortex in complete Freund’s adjuvant (Sigma Chemical
Co., St. Louis, MO, USA). Glomerulonephritis was ini-
tiated by the intravenous injection of 4.5 mg of rabbit
anti-GBM antibody into an 8- to 10-week-old female
C57BL/6. Recombinant uteroglobin [500 lg in 300 lL
of phosphate-buffered saline (PBS)/mouse for 3 days]
was delivered 1 hour after anti-GBM antibody injection
via a tail vein (N = 10). Disease control mice (N = 10)
received three doses of 300 lL of PBS after anti-GBM
antibody injection. Normal control mice received PBS
instead of anti-GBM antibody, and renal injury was stud-
ied after 7, 14, and 21 days. Proteinuria and urine cre-
atinine were measured by 24-hour urine collections at
3, 5, 7, 14, and 21 days. Urinary protein concentrations
were determined by the Bradford method. Creatinine
concentrations were measured using an autoanalyzer.
Proteinuria was normalized by urine creatinine (urine
protein/urine creatinine) (mg/mg). Serum was collected
via retro-orbital bleeding at the same time of evaluation.
All the mice were raised in specific pathogen-free animal
facility and the treatment protocol was reviewed by Seoul
National University Hospital Institute Review Board.
Histologic analysis
To assess the light microscopic appearance, 5 lm paraf-
fin sections were stained with periodic acid-Schiff (PAS)
reagent. For grading the induced glomerulonephritis, the
numbers of glomeruli forming crescent were counted in
a blinded fashion. A minimum of 50 glomeruli per mouse
kidney were evaluated, and the mean value was used as
representative for the mouse.
For immunohistochemistry study, paraffin-embedded
kidney was cut into 5 lm slices. For deparaffinization
and hydration, xylene and ethanol were used. Endoge-
nous streptoavidin activity was blocked by 3% hydrogen
peroxide (H2O2). We used biotinylated goat antirabbit
antibody (Vector Laboratory, Burlingame, CA, USA) as
primary globulin antibody for rabbit anti-GBM antibody
detection and rabbit antihuman complement-3 antibody
which is cross-reactive for mouse complement-3 (US Bio-
logical, Swampscott, MA, USA) as primary antibody for
complement-3 detection. Streptoavidin and diaminoben-
zidine (DAB) were used for immunohistochemical detec-
tion. Concentration of antibodies and exposure time were
titrated to get optimal results. Hematoxylin was used for
counterstaining.
Mesangial cell culture and proliferation assay
Mesangial cells were isolated from the glomeruli of
C57/BL6 mice using the differential sieving technique.
The glomeruli were enriched by more than 95% by cen-
trifugation. MTS/PMS analysis [17, 18] was used to as-
sess the proliferation of mesangial cells. In brief, 5 ×103
mesangial cells/well were plated in a 96-well plate. After
24 hours, the culture media was changed to Dulbecco’s
modified Eagle’s medium (DMEM) containing 0.5% fe-
tal bovine serum (FBS). Cells were washed the cells with
PBS two times after 48 hours, and the culture media
was changed for one containing 1% FBS, 1% FBS +
lipopolysaccharide (LPS) (100 ng/mL, 1 lg/mL, and 100
lg/mL, respectively), and 1% FBS + LPS (1 lg/mL) +
uterglobin (50, 100, and 150 lg/mL, respectively). After
24 hours, 20 lL of MTS (3-[4,5-dimethylthiazol-2yl-5]-
[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H tetra-
zolium) (MTS/PMS) solution (Promega, Madison, WI,
USA) was added with light shield. Light absorbance was
measured using an enzyme-linked immunosorbent as-
say (ELISA) plate reader (Spectra Max 250; Molecular
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Fig. 1. Marked attenuation of proteinuria by uretoglobin treatment at
day 7. Normal control mice (4 ± 0.7 protein/creatinine) (mg/mg) (lane
a), disease control mice received three doses of 300 lL phosphate-
buffered saline (PBS) after anti-glomerular basement membrane
(GBM) antibody injection (156 ± 18.2) (lane b), and recombinant
uteroglobin–treated mice received three doses of 0.5 mg of uteroglobin
in 300 lL PBS daily 1 hour after anti-GBM antibody injection (6 ± 1.8)
(lane c). Values are mean ± SD (N = 10/group, P = 0.0059, t test).
Devices, Sunnyvale, CA, USA) at 490 nm. Experiments
were repeated three times.
Statistics
Data were presented as the mean ± standard deviation
(SD). Comparisons between variables were made and
P values of less than 0.05 were considered statistically
significant.
RESULTS
Recombinant uteroglobin treatment prevented
the development of proteinuria and crescentic
glomerulonephritis
To assess the effects of recombinant uteroglobin on
the development of anti-GBM glomerulonephritis, we
measured the amount of proteinuria in normal controls,
a disease control (anti-GBM antibody + PBS), and in
recombinant uteroglobin-treated (anti-GBM antibody +
recombinant uteroglobin) mice. The amount of protein-
uria was normalized by urine creatinine. The protein-
uria/creatinine (mg/mg) was similar between normal con-
trol and recombinant uteroglobin-treated mice at the sev-
enth day of glomerulonephritis (4 ± 0.7, 6 ± 1.8, respec-
tively) (P =0.3059), but recombinant uteroglobin-treated
mice showed the significantly reduced amount of protein-
uria compared to that of disease control mice (6 ± 1.8 vs.
156 ± 18.2) (P = 0.0059) (Fig. 1). In disease control mice,
significant proteinuria was detectable from the third day
of illness and peaked at seventh day of illness. But in
recombinant uteroglobin-treated mice did not have sig-
nificant proteinuria throughout the observation period.
Antiproteinuric effect of recombinant uteroglobin was
maintained until 2 weeks of glomerulonephritis (recom-
binant uteroglobin-treated mice 6 ± 0.7, disease control
mice 75 ± 11.4) (P = 0.0079). After 3 weeks, the amount
of proteinuria was normalized in disease control mice to
the levels shown by the normal controls (disease control
vs. recombinant uteroglobin-treated vs. normal control
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Fig. 2. Persistent anti-proteinuric effect of recombinant uteroglobin
(rUG) after the induction of anti-glomerular basement membrane
(anti-GBM) glomerulonephritis. Antiproteinuric effect of recombinant
uteroglobin against glomerulonephritis was persistent for 2 weeks. Pro-
teinuria occurred from the third day of illness and peaked at the seventh
day of illness in anti-GBM glomerulonephritis mice. Proteinuria was re-
solved after 3 weeks of disease. Recombinant uteroglobin-treated mice
did not show any significant proteinuria throughout observation period.
At 2 weeks of disease, disease control mice showed significant amount
of proteinuria (80.4 ± 11.19) compared to recombinant uteroglobin-
treated mice (5.7 ± 2.82) (P = 0.0079, t test) (N = 5/group at 2 weeks
and 3 weeks).
Table 1. Serum creatinine levels (mg/dL) in mice with
anti-glomerular basement membrane (GBM) antibody-induced
glomerulonephritis
Normal Disease Recominant uteroglobin
Day control mice control mice treated mice
7 0.6 ± 0.05 0.5 ± 0.05 0.6 ± 0.12
14 0.5 ± 0.05 0.5 ± 0.12 0.6 ± 0.15
4 ± 1.1 vs. 3 ± 1.1 vs. 4 ± 0.6) (P = 0.567) (Fig. 2). Serum
creatinine levels were unchanged during the period of
massive proteinuria (Table 1).
To determine the correlation between the histologic
and the biochemical changes, we examined the glomeru-
lar lesions in mice. Cellular proliferation was evident in
mesangial areas (Fig. 3B) and cellular crescents devel-
oped in more than 50% of glomeruli in the disease con-
trols (Fig. 3C). The cellular crescents appeared to be of
similar age and cellularity. Also, glomerular sclerosis was
found frequently by 2 weeks of disease. Tubules and in-
terstitium revealed minimal atrophy and fibrosis. Cellu-
lar crescents reduced to 2% to 3% of glomeruli after 2
weeks in the disease control mice. Whereas after 1 week
of induction of glomerulonephritis, the glomeruli from
recombinant uteroglobin-treated mice showed no or lit-
tle crescents (Fig. 3D), and sclerotic glomerulus was not
evident by 2 weeks of disease. Overall, mice that were
treated with recombinant uteroglobin after anti-GBM
antibody injection showed similar histologic findings as
normal controls (Fig. 3A).
Uteroglobin reduced the proliferative responses
of mesangial cells to LPS stimulation and prevented
deposition of immune complexes
To investigate the renal protective characteristics of
recombinant uteroglobin, we evaluated the effect of re-
combinant uteroglobin using a mouse mesangial cell cul-
ture system. Mouse mesangial cells showed proliferative
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Fig. 3. Recombinant uteroglobin treatment prevented the develop-
ment of anti-glomerular basement membrane (anti-GBM) glomeru-
lonephritis in C57/BL6 mice. Recombinant uteroglobin treatment after
anti-GBM antibody prevented crescent formation and mesangial pro-
liferation. (A) Normal control mouse. (B) Mesangial proliferation in
disease control mice. (C) Cellular and fibrocellular crescents in disease
control mice. More than 50% of glomeruli showed crescents. (D) Re-
combinant uteroglobin-treated mice showed crescents in 2% to 3% of
glomeruli [periodic acid-Schiff (PAS) staining, original magnification
×400]. Pictures were taken at 1 week of disease.
responses to LPS stimulation in a dose-dependent man-
ner (MTS absorbance control media, 0.9 ± 0.02; media
containing LPS, 1 lg/mL, 1.1 ± 0.04; media containing
LPS, 100 lg/mL, 1.2 ± 0.08). However, with the ad-
dition of recombinant uteroglobin, the proliferation of
mesangial cells was attenuated in the presence of LPS. In-
hibitory capacity against cellular proliferation was more
evident with the increment of recombinant uteroglobin
concentration (Fig. 4).
To evaluate the notion that in vivo administration of re-
combinant uteroglobin would prevent the development
of crescentic glomerulonephritis, we evaluated immuno-
logic cascades after injection of anti-GBM antibodies. As
we expected, linear deposition of rabbit anti-GBM anti-
bodies along GBM was pathognomonic in disease control
group after 1 week of induction, and it was persistent by
2 weeks of disease (Fig. 5A). But with administration of
recombinant uteroglobin after anti-GBM antibody injec-
tion, the antibody deposition was lessened dramatically in
1 week and 2 weeks of disease induction (Fig. 5A). Also,
consistent with findings in antibody deposition, coadmin-
istration of recombinant uteroglobin prevented the depo-
sition of complement-3 on glomeruli, while complement-
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Fig. 4. Recombinant uteroglobin reduced the proliferative responses
of mesangial cells to lipopolysaccharide (LPS) stimulation in a dose-
dependent manner. LPS stimulation induced mesangial cellular prolif-
eration, but it was inhibited by the addition of recombinant uteroglobin.
Mesangial cells (5000 cells/well) were cultivated in media containing 1%
fetal bovine serum (FBS) (lane a), 1% FBS + recombinant uteroglobin
(150 lg/mL) (lane b), 1% FBS + LPS (1lg/mL) (lane c), 1% FBS + LPS
(1 lg/mL) + recombinant uteroglobin (50 lg/mL) (lane d), 1% FBS +
LPS (1 lg/mL) + recombinant uteroglobin (100 lg/mL) (lane e), and
1% FBS + LPS (1 lg/mL) + recombinant uteroglobin (150 lg/mL)
(lane f). Cellular proliferation was measured by MTS absorbance. ∗P =
0.0295; ∗∗P = 0.0027; ∗∗∗P = 0.0035 (t test). Each condition was tripli-
cated and this represents one of three independent experiments.
3 depositions were evident on disease control group
(Fig. 5B).
DISCUSSION
In present study, we demonstrate the renal protec-
tive characteristics of uteroglobin. Upon injecting recom-
binant uteroglobin, anti-GBM glomerulonephritis was
prevented in terms of the amount of proteinuria and his-
tologic changes. Also, the cellular proliferative responses
to exogenous stimuli were blunted in the presence of
recombinant uteroglobin in a dose-dependent manner.
We suggested that the inhibition of pathogenetic glob-
ulin binding to glomeruli and hence the inactivation of
immunologic cascade were the main mechanisms of the
protective role of recombinant uteroglobin in experimen-
tal crescentic glomerulonephritis.
The causes of glomerulonephritis are still obscure even
though several systemic diseases or antigens have been
associated with the development of glomerulonephritis
[19]. Genetic predisposition and environmental factors
also have been suggested to be associated with glomeru-
lonephritis [20, 21]. Anti-GBM glomerulonephritis is a
representative example of glomerulonephritis, which was
initiated by the deposition of antibodies against GBM.
Following antibody deposition, immune systems such as
the complements and inflammatory cells were activated
as mediators of glomerular injuries. Cellular prolifera-
tion, mesangial matrix expansion, and crescent formation
are responses to glomerular injuries, which, in turn, may
progress to the irreversible glomerulosclerosis.
Uteroglobin/Clara cell 10 kD (UG/CC10) was first dis-
covered in the rabbit uterus as a steroid-inducible se-
creted protein [22, 23]. Thereafter, it was found that
uteroglobin is also secreted by many types of mu-
cosal epithelial cells, including respiratory and urogenital
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Fig. 5. Antibody and complement deposi-
tion was inhibited by the injection of re-
combinant uteroglobin. Linear deposition of
anti-glomerular basement membrane anti-
bodies (anti-GBM Ab) (A) and complement-
3 (B) along GBM was evident in disease
control mice but was markedly inhibited in re-
combinant uteroglobin-treated mice. Biotiny-
lated secondary antibodies, streptoavidin,
and diaminobenzidine (DAB) were used
for immunohistochemical detection. Counter-
stained by hematoxylin (original magnifica-
tion ×400).
epithelia [9, 24]. A variety of biological activities of
uteroglobin were claimed and it is now considered that
uteroglobin is one of the most potent endogenous im-
munomodulatory and anti-inflammatory proteins [10].
Since uteroglobin was suggested as a protective factor
for glomerulonephritis in mouse models [16, 25], we and
others tried to examine the role of uteroglobin in human
glomerulonephritis [20, 26] as well as in mouse glomeru-
lonephritis model. In our anti-GBM glomerulonephritis
mouse model system, recombinant uteroglobin-treated
group secreted similar amounts of urine protein as the
normal control group (6 ± 1.8 vs. 4 ± 0.7) (P = 0.3059),
but considerably less than the disease control groups (6 ±
1.8 vs. 157 ± 18.2) (P = 0.0059). Reduction of proteinuria
by recombinant uteroglobin was most evident on sev-
enth day of illness. Thereafter the amount of urine pro-
tein decreased continually, and by the end of third week,
even the disease control group showed the same amount
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of proteinuria as the normal control group (Fig. 2).
In a murine model of glomerulonephritis using rabbit
antimouse GBM antibody, the disease process is usually
reported to be irreversible [3]. The reversibility of the dis-
ease in our model might be due to the difference in the
amount of anti-GBM globulin antibody injected or the
different protocols used. Most of the models described
to date include two consecutive antibody injections or
prior sensitization with normal rabbit IgG. In a prelim-
inary study involving dual antibody injection protocols,
we were able to obtain a consistent induction of glomeru-
lonephritis, but the low survival rate of mice during the ex-
periment period prevented us from continuing these dual
injection protocols. Recombinant uteroglobin coadmin-
istration dramatically improved the histologic changes
which were consistent with the reduced proteinuria. Cel-
lular crescent formation and mesangial cell changes were
hardly observed in the recombinant uteroglobin-treated
group. In the disease control group, on day 7, we observed
an expansion of mesangial cells and crescent formation
in more than 50% of the glomeruli, whereas in recombi-
nant uteroglobin-treated groups, these were found in 2%
to 3% of the glomeruli (Fig. 3). However, serum creati-
nine level did not change before and after the induction
of glomerulonephritis, suggesting that the anti-GBM an-
tibody we used was sufficient to induce disease but insuf-
ficient to reduce renal function. Another interpretation
could be that our observation period was too short to
evaluate renal function properly.
We used mesangial cell culture system to evaluate the
direct effect of recombinant uteroglobin on cellular com-
ponents of kidney because mesangial cells are responsi-
ble for the development of various glomerulonephritis.
LPS-induced mesangial cell activation and proliferation
has been reported [13, 27]. Moreover, the severity of in-
flammation in glomeruli paralleled the LPS concentra-
tion [28]. In our primary mouse mesangial culture system,
mesangial cells responded proportionately to increased
concentrations of LPS. On using a constant amount of
LPS (1 lg/mL), uteroglobin prevented mesangial cell pro-
liferation in a dose-dependent manner. This in vitro effect
of mesangial cell modulation would have an impact on re-
duced mesangial cell expansion and crescent formation.
As it was proposed that uteroglobin prevented IgA de-
position on glomeruli [16], we investigated the influence
of recombinant uteroglobin on immune complex depo-
sition. As shown in Figure 5, recombinant uteroglobin
showed profound prevention of pathogenic globulin
antibody deposition, and blocked the immunologic
downstream cascade. Inhibition of cellular proliferation
to noxious stimuli (LPS in our system) and decreased im-
mune complex activation may be the central protective
mechanisms exerted by recombinant uteroglobin in the
murine glomerulonephritis model.
To our knowledge, this is the first demonstration that
recombinant uteroglobin leads to the prevention of ex-
perimental glomerulonephritis. We believe that an un-
derstanding the way in which this protein work could
have therapeutic implications for the treatment of human
glomerulonephritis.
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